1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,910 | 9,160 | 09:53 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | Selvita S.A.: Selvita Reports Rebound in H2 2024 and 11% Increase in Backlog for 2025 | 190 | PR Newswire | KRAKOW, Poland, March 27, 2025 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of Europe's leading preclinical CROs, has announced its financial results for 2024... ► Artikel lesen | |
| SELVITA Aktie jetzt für 0€ handeln | |||||
| 21.11.24 | Selvita Reports Significant Recovery in H2 2024, Sees Promising Outlook for the Future | 158 | PR Newswire | KRAKÓW, Poland, Nov. 21, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published... ► Artikel lesen | |
| 24.09.24 | Selvita S.A.: Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024 | 393 | PR Newswire | KRAKÓW, Poland, Sept. 24, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published its financial results for Q2 2024... ► Artikel lesen |
3 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,498 | +1,43 % | Palatin: Bremelanotide-Tirzepatide Combination Achieves Primary Endpoint In Phase 2 Obesity Study | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly statistically significant. The... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,720 | +2,26 % | COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer | ||
| HALOZYME THERAPEUTICS | 56,02 | -3,55 % | Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method | NEW YORK CITY (dpa-AFX) - Halozyme Therapeutics, Inc. (HALO), Monday announced that Bristol Myers Squibb (BMY) received a positive opinion from the Committee for Medicinal Products for Human... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 2,015 | -1,32 % | AbCellera Biologics Aktie: Die Falle schnappt zu? | AbCellera Biologics Inc. (ABCL) hat kürzlich Informationen zu seinen Forschungsinitiativen und finanziellen Ergebnissen veröffentlicht, die den laufenden Übergang zu einem Biotechnologieunternehmen... ► Artikel lesen | |
| GLOW LIFETECH | 0,048 | 0,00 % | Glow LifeTech Corp.: Glow Lifetech Triples Capacity via Automated Production Line as MOD Becomes #2 Oils SKU in Ontario | Toronto, Ontario--(Newsfile Corp. - March 25, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is accelerating its expansion with the acquisition of a... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 223,80 | -1,06 % | Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results | HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd.: BioLineRx Reports 2024 Financial Results and Provides Corporate Update | - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases -
- Executed license... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 1,540 | -1,91 % | Whitehawk Therapeutics files to sell 41.67M shares of common stock for holders | ||
| MINERVA NEUROSCIENCES | 1,490 | -1,32 % | Minerva Neurosciences, Inc: Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates | BURLINGTON, Mass., Feb. 25, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,449 | +9,82 % | Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission | ||
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs CEO David Dodd erwirbt Stammaktien im Wert von 10.800 US-Dollar | ||
| OVID THERAPEUTICS | 0,302 | -3,21 % | Ovid Therapeutics Aktie: Rückschritte statt Erfolge? | Biopharma-Unternehmen kämpft mit Kursverlusten trotz gefüllter Kassen und vielversprechender Entwicklungen bei Medikamentenkandidaten für neurologische Erkrankungen Ovid Therapeutics hat kürzlich Updates... ► Artikel lesen | |
| COCRYSTAL | 1,260 | -1,56 % | Cocrystal Pharma, Inc. - 10-K, Annual Report | ||
| PRECISION BIOSCIENCES | 4,200 | -4,55 % | Precision Biosciences-Direktor Kevin Buehler kauft Aktien im Wert von 21.122 US-Dollar |
Das Unternehmen SELVITA SA kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,34 % bei einem Aktienkurs von 8,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SELVITA SA finden Sie auf Wallstreet Online.
